- About Us
- Cell Therapy
- Animal Medicine
- Products & Services
- IR/PR
- Contact Us
DC Technology
Dendritic Cell Therapy
Treatments involving the differentiation of dendritic cells expressing MHC with disease-related antigens and re-introduction of cells into the patient's body induce activation or suppression of antigen-specific immune responses to modulate responses.
Dendritic cells (DC) are known as natural adjuvants of the human immune system, and not only induce early immunity but also perform a central role in immune regulation as the core antigen-presenting cell (APC), and this immunomodulation cell therapy uses differentiated dendritic cells with expressed antigens that are reintroduced into the patient’s body.
Characteristics of Dendritic Cell Therapy
Dendritic cells are antigen-presenting cells that perform antigen presentation to T cells, and are present in dendritic form in the intercellular spaces of various tissues including lymph nodes, spleen, thymus, skin, or other tissues.
Dendritic cells absorb antigens intracellularly and present various antigen samples to T cells along with major histocompatibility complex (MHC) class I or class II molecules, which play an important role in T cell activation. Also, dendritic cells differentiate into various levels of maturity according to their type and surrounding environmental signals to exist as immature, semi-mature, or mature dendritic cells, and semi-mature dendritic cells are known to be related to immune tolerance, which is different from mature ones.
Pharos Vaccine is performing clinical research on the maturation conditions of immune-tolerant dendritic cells, type and characteristics of expressed antigens, administration dose, administration route, and administration schedules, for effective use against autoimmune diseases.
Blood Collection
Isolation & Activation
Differentiation &
Ag Pulsation
Cell Maturation
Infusion
Pharos Vaccine is applying these characteristics of dendritic cells to development of tolerogenic dendritic cells (tDC) to induce immune tolerance with an aim of treating autoimmune diseases such as rheumatoid arthritis and myocarditis. These cells are designed to move to nearby lymph nodes when injected into the body and react with naïve T cells to induce specific regulatory T cells, and are fundamental treatments with significantly lower rates of adverse events.
Paper
Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice. Immunol Invest. 2016 Aug;45(6)553-65.
Rosiglitazone-mediated dendritic cells ameliorate collagen-induced arthritis in mice. Biochem Pharmacol. 2016 Sep 1;11585-93.
Infarcted Myocardium-Primed Dendritic Cells Improve Remodeling and Cardiac Function After Myocardial Infarction by Modulating the Treg and Macrophage Polarization. Circulation. 2017 Apr 11;135(15):1441-1457.
Dendritic Cell-Based Immunotherapy for Solid Tumors_Transl Oncol. 2018 Apr 5;11(3)686-690
Rsad2 is necessary for mouse dendritic cell maturation via the IRF7-mediated signaling pathway_Cell Death and Disease (2018)9,823
Synergistic Effect of Tolerogenic Dendritic Cells and Etanercept on a Collagen-induced Arthritis Animal Model. JHTB Vol. 28(3) 265-272, 2019
Pdlim4 is essential for CCR7-JNK–mediated dendritic cell migration and F-actin–related dendrite formation. FASEB Vol 33.Oct 2019.
The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function_ Journal of Cancer 2020,Vol.II 769-774
